EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

14513J2J-MC-JZLH-EMBER-4Open (affiliates only)EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of RecurrenceL2J-MC-JZLHNCT05514054Industrial; InstitutionalAdultTreatmentIIIGlobalBreastWhitaker, KristenMedstar Washington Hospital Center : Stacy MalloyBreastOncology GroupMHRI Washington Cancer Institute7263Julie CastleJulie Castle+1 202-687-2209bickmorj@georgetown.eduClinical Research Nurse 7311Antonella NovielliAntonella Novielli+1 202-784-3923+1 202-687-3372noviella@georgetown.eduClinical Research Nurse 10787Stacy MalloyStacy MalloyStacy.K.Malloy@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>